Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 3, 2013, Pages 274-279

  Fung, Filgen Y ^a,b   Li, Madeline ^a,c   Breunis, Henriette ^a   Timilshina, Narhari ^a   Minden, Mark D ^a,d   Alibhai, Shabbir M H ^a,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute myeloid leukemia; Cancer related fatigue; Chemokines; Cytokines; Interferon; Interleukins; Quality of life; Tumor necrosis factor

Indexed keywords

ALPHA CHEMOKINE; CYTARABINE; CYTOKINE; DAUNORUBICIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTROCHEMICAL ANALYSIS; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; FATIGUE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; YOUNG ADULT;

EID: 84872971920     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.013     Document Type: Article

References (44)

1. National Cancer Institute. SEER Stat Fact Sheets: Acute myeloid leukemia; 2010.
2. Kantarjian H., Beran M., Cortes J., O'Brien S., Giles F., Pierce S., et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006, 106:1099-1109.
3. Schumacher A., Wewers D., Heinecke A., Sauerland C., Koch O.M., van de Loo J., et al. Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia. Leuk Res 2002, 26:355-362.
4. Sekeres M.A., Stone R.M., Zahrieh D., Neuberg D., Morrison V., De Angelo D.J., et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18:809-816.
5. Alibhai S.M.H., Leach M., Kermalli H., Gupta V., Kowgier M.E., Tomlinson G.A., et al. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol 2007, 64:19-30.
6. Bower J.E. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 2007, 21:863-871.
7. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007, 21:413-427.
8. Alibhai S.M., Leach M., Kowgier M.E., Tomlinson G.A., Brandwein J.M., Minden M.D. Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status. Leukemia 2007, 21:845-848.
9. Alibhai S.M.H., Leach M., Gupta V., Tomlinson G.A., Brandwein J.M., Saiz F.S., et al. Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia. Crit Rev Oncol Hematol 2009, 69:168-174.
10. Cella D., Lai J.S., Chang C.H., Peterman A., Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002, 94:528-538.
11. Jager A., Sleijfer S., van der Rijt C.C. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?. Eur J Cancer 2008, 44:175-181.
12. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008, 100:1155-1166.
13. Dantzer R., Capuron L., Irwin M.R., Miller A.H., Ollat H., Perry V.H., et al. Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 2008, 33:18-29.
14. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
15. El-Gohary G.M., Azzam H.M., Ahmed O.I., El-Shokry M.H. Pro-inflammatory cytokines and depression in patients with acute leukemia. Egypt J Immunol 2008, 15:13-24.
16. Panju A.H., Danesh A., Minden M.D., Kelvin D.J., Alibhai S.M.H. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer 2009, 17:539-546.
17. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
18. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria. Treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
19. Mohamedali H., Breunis H., Timilshina N., Brandwein J.M., Gupta V., Li M., et al. Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res 2012, 36:1241-1248.
20. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997, 34:13-19.
21. Bruera E., Kuehn N., Miller M.J., Selmser P., Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991, 7:6-9.
22. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
23. Jones L.W., Eves N.D., Mackey J.R., Peddle C.J., Haykowsky M., Joy A.A., et al. Systemic inflammation, cardiorespiratory fitness, and quality of life in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:194-195.
24. Rich T., Innominato P.F., Boerner J., Mormont M.C., Iacobelli S., Baron B., et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005, 11:1757-1764.
25. Wratten C., Kilmurray J., Nash S., Seldon M., Hamilton C.S., O'Brien P.C., et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 2004, 59:160-167.
26. Khanna D., Pope J.E., Khanna P.P., Maloney M., Samedi N., Norrie D., et al. The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol 2008, 35:2339-2343.
27. Cella D., Eton D.T., Lai J.S., Peterman A.H., Merkel D.E. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002, 24:547-561.
28. King M.T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996, 5:555-567.
29. Greenberg D.B., Gray J.L., Mannix C.M., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 1993, 8:196-200.
30. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006, 12:2759-2766.
31. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002, 64:604-611.
32. Kraemer H.C., Morgan G.A., Leech N.L., Gliner J.A., Vaske J.J., Harmon R.J. Measures of clinical significance. J Am Acad Child Adolesc Psychiatry 2003, 42:1524-1529.
33. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
34. Liu L., Callahan M.K., Huang D., Ransohoff R.M. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 2005, 68:149-181.
35. Schmitt A., Li L., Giannopoulos K., Greiner J., Reinhardt P., Wiesneth M., et al. Quantitative expression of toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion 2008, 48:861-870.
36. Fang Y.S., Zhu L.M., Sun Z.G., Yu L.Z., Xu H. Tumor necrosis factor-alpha pathway plays a critical role in regulating interferon-gamma induced protein-10 production in initial allogeneic human monocyte-endothelial cell interactions. Transplant Proc 2012, 44:993-995.
37. Neville L.F., Mathiak G., Bagasra O. The immunobiology of interferon-gamma inducible protein 10kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997, 8:207-219.
38. Adler M.W., Geller E.B., Chen X., Rogers T.J. Viewing chemokines as a third major system of communication in the brain. AAPS J 2005, 7:E865-E870.
39. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P.C. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 2011, 41:761-767.
40. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003, 17(Suppl. 1):S112-S118.
41. Tookman A.J., Jones C.L., DeWitte M., Lodge P.J. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer 2008, 16:1131-1140.
42. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006, 24:1852-1859.
43. Madhusudan S., Foster M., Muthuramalingam S.R., Braybrooke J.P., Wilner S., Kaur K., et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:6528-6534.
44. Hyrich K.L., Watson K.D., Isenberg D.A., Symmons D.P. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 2008, 47:1441-1443.